Research programme: plasma kallikrein inhibitors - Attune Pharmaceuticals

Drug Profile

Research programme: plasma kallikrein inhibitors - Attune Pharmaceuticals

Alternative Names: ATN-035; ATN-249

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Attune Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hereditary angioedema

Most Recent Events

  • 23 May 2017 Pharmacokinetic and safety data from preclinical trials in Hereditary angioedema released by Attune Pharmaceuticals
  • 06 Mar 2017 Attune Pharmaceuticals plans phase I pharmacokinetic studies for Hereditary angioedema (In volunteers)
  • 06 Mar 2017 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Hereditary angioedema presented at the 2017 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top